Home / Market News / $CAPR
benzinga Corporate Catalyst Impact 85/100 ● positive

Capricor Therapeutics Stock Surges: What's Going On?

Sep 30, 2026, 3:18 PM UTC · Primary ticker $CAPR

Capricor Therapeutics announced positive 24-month clinical data from its Phase 3 HOPE-3 trial for deramiocel in Duchenne Muscular Dystrophy, showing a significant slowing of upper-limb function decline. This data directly supports its revised Biologics License Application (BLA) and led to a 'Buy' upgrade and increased price target from B. Riley, causing a substantial stock rally.

Capricor Therapeutics (CAPR) experienced a significant stock surge following the release of positive 24-month data from its HOPE-3 trial for deramiocel in Duchenne Muscular Dystrophy. This data is crucial as it directly supports the company's amended Biologics License Application (BLA) to the FDA, which focuses on preserving upper-limb function after a previous advisory panel rejection for a broader indication. The positive clinical results led B. Riley to upgrade CAPR from Neutral to Buy, raising its price target from $5 to $21, indicating strong analyst confidence. This development provides critical support for the biotechnology firm, offering a potential path to regulatory approval and a rebound from previous setbacks, making it a significant short-term opportunity for traders betting on FDA approval.

$CAPR positive Positive clinical data and analyst upgrade
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.